Adicet opens enrollment for adi-270 phase 1 clinical trial in metastatic/advanced clear cell renal cell carcinoma

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the phase 1 clinical trial evaluating adi-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccrcc). “solid tumors represent one of the highest unmet medical needs in oncology and have yet to benefit from th.
ACET Ratings Summary
ACET Quant Ranking